Biosensor analysis of β2-glycoprotein I-reactive autoantibodies: Evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies

Clinical Chemistry

Volumn 53, Issue 6, 2007, Pages 1137-1143

  Metzger, Jochen ^a   Von Landenberg, Philipp ^b   Kehrel, Marcus ^a   Buhl, Alexander ^a   Lackner, Karl J ^b   Luppa, Peter B ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; BACTERIAL ANTIGEN; VIRUS ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BIOSENSOR; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA INFECTIOSUM; HUMAN; INFECTION; PROTEIN IMMOBILIZATION; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; COMPARATIVE STUDY; CROSS REACTION; GENETIC PROCEDURES; IMMUNOLOGY; PARVOVIRUS; PROTEIN BINDING; TREPONEMA PALLIDUM; VIRUS INFECTION;

PARVOVIRUS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOSENSING TECHNIQUES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN ISOTYPES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PROTEIN BINDING; SURFACE PLASMON RESONANCE; SYPHILIS; TREPONEMA PALLIDUM;

EID: 34249875995     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.079632     Document Type: Article

References (31)

1. Bertolaccini M, Khamashta MA. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 2006;15:172-8.
2. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
4. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544-7.
5. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
6. Matsuda J, Saitoh N, Gohchi K, Tsukamoto M. Distinguishing beta2-glycoprotein I dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween-20. Br J Haematol 1993;85:799-802.
7. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999;13:347-55.
8. Arvleux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using beta2-glycoprotein as an antigen. J Immunol Methods 1991;143:223-9.
9. Martinuzzo ME, Forastiero RR, Carreras LO. Anti-beta2-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397-402.
10. Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin and anti-beta2-GPI antibodies in a large saries of European patients with systemic lupus erythematosus: prevalence and clinical associations: European Concerted Action on the immunogenatics of SLE. Scand J Rheumatol 1999;28: 344-51.
11. Bertolaccini ML, Atsumi T, Escudero-Contreras A, Khamashta MA, Hughes GR. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637-43.
12. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540-3.
13. Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006;25:199-204.
14. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478-82.
15. Zoghlami-Rintelen C, Vormittag R, Sailer T, Lehr S, Quehenberger P, Rumpold H, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with lupus anticoagulant. J Thromb Haemost 2005;3:1160-5.
16. Buschmann C, Fischer C, Ochsenhirt V, Neukirch C, Lackner KJ, von Landenberg P. Generation and characterization of three monoclonal IgM antiphospholipid antibodies recognizing different phospholipid antigens. Ann N Y Acad Sci 2005;1051:240-54.
17. Bozic B, Cucnik S, Kveder T, Rozman B. Avidity of anti-beta-2- glycoprotein I antibodies. Autoimmun Rev 2005;4:303-8.
18. Guidance for sponsors institutional review boards clinical investigators and FDA staff. OMB control no. 0910-0582, issued 09/25/2006. http://www.fda.gov/cdrh/olvd/guidance/1588.html (accessed April 13, 2007).
19. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-11.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Ulman A. Formation and structure of self-assembled monolayers. Chem Rev 1996;96:1533-54.
22. von Landenberg C, Lacknar KJ, von Landenberg P, Lang B, Schmitz G. Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999;13:215-23.
23. Cabiedes J, Cabrel AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-4 than with antiphospholipid antibodies. J Rheumatol 1995; 22:1899-906.
24. Sanfilippo SS, Khamashta MA, Atsumi T, Amengual O, Bertolaccini ML, D'Cruz D, et al. Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. J Rheumatol 1998;25:2131-4.
25. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997;40:103-8.
26. Santiago M, Martinelli R, Ko A, Reis EA, Fontes RD, Nascimento EG, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001; 19:425-30.
27. Freuenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunoblology 2005;210: 799-805.
28. Azeredo da Silveire S, Kikuchi S, Fossati-Jimack L, Moll T, Saito T, Verbeek JS, et al. Complamant activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 2002;195:665-72.
29. Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999;93:942-51.
30. Ito MR, Teresaki S, Kondo E, Shiwaku H, Fukuoka Y, Nose M. Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies. Clin Exp Immunol 2000;119:340-5.
31. Fulpius T, Spertini F, Reininger L, Izul S. Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor. Proc Natl Acad Sci U S A 1993;90:2345-9.